Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Glioblastoma × Standard of Care × Clear all

Phase

Phase NA 2 Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Stomach Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Muscular Atrophy 1 Mouth Neoplasms 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Hemorrhage 1 Hematologic Neoplasms 1 Glioblastoma 1 Gallbladder Neoplasms 1 Colonic Neoplasms 1 Child Nutrition Disorders 1 COVID-19 1 Breast Neoplasms 1

Interventions

Temozolomide 8 Lomustine 4 vocimagene amiretrorepvec 2 Radiation 2 veliparib 1 regorafenib 1 carbon-11 acetate 1 antisecretory factor 1 Sunitinib 1 Standard of Care 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 GDC-0084 1 Flucytosine 1 Etoposide 1 Drug Therapy 1 Disulfiram 1 Dianhydrogalactitol 1 DNA 1 Copper 1 Carbon-11 1 Bevacizumab 1 Alkylating Agents 1 AZD1390 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03548571 2024-04-03

DEN-STEM

Oslo University Hospital

Phase 2/3 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡